BR112013000629A2 - derivados de amina espiro-cíclicos como moduladores s1p - Google Patents
derivados de amina espiro-cíclicos como moduladores s1pInfo
- Publication number
- BR112013000629A2 BR112013000629A2 BR112013000629A BR112013000629A BR112013000629A2 BR 112013000629 A2 BR112013000629 A2 BR 112013000629A2 BR 112013000629 A BR112013000629 A BR 112013000629A BR 112013000629 A BR112013000629 A BR 112013000629A BR 112013000629 A2 BR112013000629 A2 BR 112013000629A2
- Authority
- BR
- Brazil
- Prior art keywords
- optionally substituted
- alkyl
- halogen
- fluorine atoms
- substituted
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000001153 fluoro group Chemical group F* 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- -1 phenoxy, benzyl Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000004980 cyclopropylene group Chemical group 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
derivados de amina espiro-cíclicos como moduladores s1p. a presente invenção refere-se aos derivados de amina espiro-cíclica da fórmula (i) em que r1 é selecionado de ciano, (2-4c) alquenila, (2-4c) alquinila, (1-4c) alquila cada uma opcionalmente substituída com cn ou um ou mais átomos de flúor, (3-6c) cicloalquila, (4-6c) cicloalquenila ou um grupo (8-10c) bicíclico, cada uma opcionalmente substituído com halogêneo ou (1-4c) alquila, fenila, bifenila, naftila, cada uma opcionalmente substituída com um ou mais substituintes independentemente selecionados de halogêneo, ciano, (1-6c) alquila opcionalmente substituída com um ou mais átomos de flúor, (1-6c) alcóxi opcionalmente substituído com um ou mais átomos de flúor, amino, di(1-4c) alquilamino e (3-6c) cicloalquila opcionalmente substituída com fenila que pode ser substituída com (1-4c) alquila ou halogêneo, fenila substituída com fenóxi, benzila, benzilóxi, feniletila ou heterocido monocíclico, cada uma opcionalmente substituído com (1-4c) alquila opcionalmente substituída com um ou mais átomos de flúor, heterocido monocíclico de forma opcional independentemente substituído com halogêneo, (1-6c) alquila opcionalmente sibstituída com u ou mais átomos de flúor, (3-6c) cicloalquila, ou fenila opcionalmente substituída com (1-4c) alquila ou halogêneo, e heterociclo bicíclico opcionalmente substituído com halogêneo ou (1-4c) alquila opcionalmente substituída com um ou mais átomos de flúor; -y-(c~ n~-alquileno)-x- é um grupo de ligação em que y é ligado a r1 e selecionado de uma ligação, -o-, co-, -s-, -so-, -so~ 2~, -nh-, -ch=ch-, -c(cf~ 3~)= ch-, -c<sym>c-, -ch~ 2~-o-, -o-co-, -co-o-, -co-nh-, -nh-co-, e trans-ciclopropileno; n é um número inteiro de 0 a 10; e x é ligado ao componente de fenileno/piridila e selecionado de uma ligação, -o-, -s-, -so-, -so~ 2~- , -nh-, -co-, -ch=ch-, e trans-ciclopropileno; r2 é h ou independentemente selecionado de um ou mais substituintes selecionados de halogêneo, (1-4c) alcóxi e (1-4c) alquila opcionalmente substituída com um ou mais átomos de flúor; e r3 é (1-4c) alquileno-r4 em que o grupo de alquileno pode ser substituído com um ou mais átomos de halogêneo ou com (ch~ 2~)~ 2~ para formar um componente de ciclopropila, ou r3 é (3-6c) cicloalquileno-r4, -ch~ 2~-(3-6c)cicloalquilen-r4, (3-6c) cicloalquileno-ch~ 2- r4 ou -co-ch~ 2~-r4, em que r4 é -oh, -po~ 3~ h~ 2~-r4, em que r4 é -oh, -po~ 3~h~ 2~, opo~ 3~h~ 2~, -cooh, -coo(1-4c) alquila ou tetrazol-5-ila; q é uma ligação ou -o-; r5 é h ou independentemente selecionado de um ou mais halogêneos; z é ch, cr2 ou n; e a representa uma estrutura de anel de morfolina ou uma amina cíclica de 5,6 e 7 membros; ou um sal, solvato ou hidrato farmaceuticamente aceitável destes ou um ou mais de seus n-óxidos. oc compostos da invenção possuem afinidade aos receptores de s1p e podem ser usados no tratamento, alívio ou prevenção de doenças ou condições em que (a) o(s) receptor(es) de s1p está (estão) envolvido(s).
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36278210P | 2010-07-09 | 2010-07-09 | |
EP10169104.6 | 2010-07-09 | ||
EP10169104 | 2010-07-09 | ||
US61/362,782 | 2010-07-09 | ||
US201161444186P | 2011-02-18 | 2011-02-18 | |
US61/444,186 | 2011-02-18 | ||
EP11154961 | 2011-02-18 | ||
EP11154961.4 | 2011-02-18 | ||
PCT/EP2011/061599 WO2012004378A1 (en) | 2010-07-09 | 2011-07-08 | Spiro-cyclic amine derivatives as s1p modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013000629A2 true BR112013000629A2 (pt) | 2016-05-24 |
BR112013000629B1 BR112013000629B1 (pt) | 2020-12-15 |
Family
ID=44315247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013000629-3A BR112013000629B1 (pt) | 2010-07-09 | 2011-07-08 | Derivados de amina espiro-cíclicos como moduladores s1p |
Country Status (23)
Country | Link |
---|---|
US (4) | US10179791B2 (pt) |
EP (2) | EP2590955B9 (pt) |
JP (1) | JP5922115B2 (pt) |
KR (1) | KR101889695B1 (pt) |
CN (1) | CN103097364B (pt) |
AR (1) | AR082135A1 (pt) |
AU (1) | AU2011275760B2 (pt) |
BR (1) | BR112013000629B1 (pt) |
CA (1) | CA2804143C (pt) |
DK (1) | DK2590955T3 (pt) |
ES (1) | ES2606137T3 (pt) |
HK (1) | HK1184153A1 (pt) |
IL (1) | IL224049B (pt) |
MX (1) | MX347423B (pt) |
NZ (1) | NZ605486A (pt) |
PL (1) | PL2590955T3 (pt) |
PT (1) | PT2590955T (pt) |
RU (2) | RU2602800C2 (pt) |
SG (1) | SG186926A1 (pt) |
TW (2) | TW201643169A (pt) |
UY (1) | UY33497A (pt) |
WO (1) | WO2012004378A1 (pt) |
ZA (1) | ZA201300153B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
USRE48301E1 (en) | 2010-07-09 | 2020-11-10 | Abbvie B.V. | Fused heterocyclic derivatives as S1P modulators |
CN102250035A (zh) * | 2011-06-10 | 2011-11-23 | 北京富卡生物技术有限公司 | 二芳基取代-1,3,4-噁二唑化合物的合成方法和其药物用途 |
US8642585B2 (en) * | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
US8809376B2 (en) | 2012-04-30 | 2014-08-19 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
WO2014086712A1 (en) | 2012-12-07 | 2014-06-12 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
KR101598612B1 (ko) * | 2013-08-29 | 2016-02-26 | 재단법인 아산사회복지재단 | Dpp-4 억제제를 포함하는 혈관 또는 심장판막 석회화의 예방 또는 치료용 조성물 |
CN107253903B (zh) * | 2016-06-20 | 2020-11-24 | 北京海步医药科技股份有限公司 | 制备一种能够结合s1p受体化合物及其中间体的方法 |
EP3535244A1 (en) | 2016-11-02 | 2019-09-11 | Abbvie Deutschland GmbH & Co. KG | Spiro-compounds as s1p modulators |
JP7023969B2 (ja) | 2017-01-26 | 2022-02-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
CN110312714B (zh) | 2017-01-26 | 2022-12-09 | 勃林格殷格翰国际有限公司 | 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途 |
WO2018138028A1 (en) | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
JP7049353B2 (ja) | 2017-02-08 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 |
EP3590929B1 (en) * | 2017-02-28 | 2021-09-15 | Medshine Discovery Inc. | Spiro compound and use thereof |
CN110092774B (zh) * | 2018-01-29 | 2022-04-08 | 中国科学院上海药物研究所 | 芳香丙酸类衍生物、及其制备方法和用途 |
US11458124B2 (en) | 2018-07-12 | 2022-10-04 | UCBBiopharma Srl | Spirocyclic indane analogues as IL-17 modulators |
AU2020373047A1 (en) | 2019-10-31 | 2022-05-19 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
WO2022117553A1 (en) * | 2020-12-01 | 2022-06-09 | AbbVie Deutschland GmbH & Co. KG | Spiro-cyclic amine derivatives as s1p modulators |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3962259A (en) | 1973-12-12 | 1976-06-08 | American Hoechst Corporation | 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof |
US3980787A (en) * | 1975-08-25 | 1976-09-14 | American Hoechst Corporation | 3-Phenylspiro[isobenzofuran-1,4'-piperidine]sulfenamides and derivatives |
SU1069387A1 (ru) | 1982-07-01 | 1985-11-30 | Институт физико-органической химии и углехимии АН УССР | Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием |
GB2228432A (en) | 1989-01-13 | 1990-08-29 | Grayston Central Services | Multi-role machine for heating and coating pipe welds. |
IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
JPH03206042A (ja) | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
JP2681589B2 (ja) | 1992-12-28 | 1997-11-26 | 日揮株式会社 | 配管溶接継手の熱処理方法 |
JPH072848A (ja) | 1993-04-23 | 1995-01-06 | Sankyo Co Ltd | モルホリンおよびチオモルホリン誘導体 |
GB9522845D0 (en) * | 1995-11-08 | 1996-01-10 | Smithkline Beecham Plc | Novel compounds |
JP3822680B2 (ja) | 1996-08-30 | 2006-09-20 | 新日本製鐵株式会社 | 誘導加熱された接合部の冷却方法および冷却装置 |
TWI243173B (en) * | 1999-11-17 | 2005-11-11 | Akzo Nobel Nv | Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives |
US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
RU2275371C2 (ru) | 2000-04-21 | 2006-04-27 | Шионоги Энд Ко., Лтд. | Производные оксадиазола, обладающие противоопухолевым действием, лекарственное средство, их содержащее, и способ лечения |
FR2822727A1 (fr) | 2001-04-03 | 2002-10-04 | Gesal Ind | Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement |
JP3649223B2 (ja) | 2003-01-08 | 2005-05-18 | 株式会社日立製作所 | 配管系の熱処理方法および熱処理装置 |
JP4648899B2 (ja) | 2003-06-12 | 2011-03-09 | ビーティージー・インターナショナル・リミテッド | 神経賦活性化合物としての環式ヒドロキシルアミン |
EP1663188B1 (en) | 2003-09-12 | 2016-08-10 | Newron Sweden AB | Treatment of disorders of the nervous system |
US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
JP2007516298A (ja) | 2003-12-23 | 2007-06-21 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物 |
GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
JP2007530656A (ja) * | 2004-03-29 | 2007-11-01 | ファイザー株式会社 | ORL1受容体拮抗薬としてのαアリールまたはヘテロアリールメチルβピペリジノプロパンアミド化合物 |
GB0409744D0 (en) | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
CA2564994A1 (en) | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
JP4491334B2 (ja) | 2004-12-01 | 2010-06-30 | 日立Geニュークリア・エナジー株式会社 | 配管の熱処理方法および装置 |
GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
JP4599250B2 (ja) | 2005-08-10 | 2010-12-15 | 株式会社東芝 | 高周波誘導加熱時外面温度制御方法および当該制御装置 |
JP2007063642A (ja) | 2005-09-01 | 2007-03-15 | Hitachi Ltd | 残留応力改善方法と高周波誘導加熱用コイル |
CA2629018C (en) * | 2005-11-10 | 2013-12-31 | Banyu Pharmaceutical Co., Ltd. | Aza-substituted spiro derivative |
WO2007057775A1 (en) | 2005-11-21 | 2007-05-24 | Pfizer Limited | Spiropiperidine derivatives |
RU2008130094A (ru) * | 2005-12-22 | 2010-01-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы мускариновых рецепторов |
EP1981497A2 (en) | 2006-01-27 | 2008-10-22 | F.Hoffmann-La Roche Ag | Use of substituted 2-imidazole of imidazoline derivatives |
ES2338716T3 (es) | 2006-01-27 | 2010-05-11 | F.Hoffmann-La Roche Ag | Uso de derivados de 4-imidazol para trastornos del snc. |
JP2009528363A (ja) | 2006-02-28 | 2009-08-06 | ヘリコン セラピューティクス,インコーポレイテッド | Pde4インヒビターとしての治療用ピペラジン |
WO2007109334A2 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | Sip receptor modulating compounds and use thereof |
GB0608452D0 (en) * | 2006-04-27 | 2006-06-07 | Glaxo Group Ltd | Novel compounds |
EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
JP2010502675A (ja) | 2006-09-08 | 2010-01-28 | ノバルティス アクチエンゲゼルシャフト | リンパ球相互作用が介在する疾患または障害を処置するために有用なn−ビアリール(ヘテロ)アリールスルホンアミド誘導体 |
BRPI0720478A2 (pt) * | 2006-12-21 | 2014-01-14 | Abbott Laboratoires | Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato |
WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
MX2009011421A (es) | 2007-04-23 | 2009-12-15 | Novartis Ag | Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p. |
WO2009084501A1 (ja) | 2007-12-27 | 2009-07-09 | Asahi Kasei Pharma Corporation | スルタム誘導体 |
CA2710474A1 (en) | 2008-01-24 | 2009-07-30 | Ucb Pharma, S.A. | Compounds comprising a cyclobutoxy group |
UA100877C2 (ru) | 2008-01-30 | 2013-02-11 | Сефалон, Інк. | Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3) |
WO2009097567A1 (en) * | 2008-01-30 | 2009-08-06 | Cephalon, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
US20090321144A1 (en) | 2008-06-30 | 2009-12-31 | Wyble Kevin J | Protecting an element from excessive surface wear by localized hardening |
UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
US9051275B2 (en) | 2010-02-04 | 2015-06-09 | Laboratories Del Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
CN101812058B (zh) | 2010-04-13 | 2012-03-21 | 湖南大学 | 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用 |
TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
US10179971B2 (en) | 2014-03-21 | 2019-01-15 | Iogen Energy Corporation | Method for processing a cellulosic feedstock at high consistency |
BR112022008137A2 (pt) | 2019-10-31 | 2022-07-19 | Escape Bio Inc | Processos para preparar um modulador de receptor s1p |
AU2020373047A1 (en) | 2019-10-31 | 2022-05-19 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
-
2011
- 2011-07-07 TW TW105117687A patent/TW201643169A/zh unknown
- 2011-07-07 TW TW100124108A patent/TWI543984B/zh active
- 2011-07-08 AU AU2011275760A patent/AU2011275760B2/en active Active
- 2011-07-08 EP EP11730314.9A patent/EP2590955B9/en active Active
- 2011-07-08 CN CN201180033970.6A patent/CN103097364B/zh active Active
- 2011-07-08 ES ES11730314.9T patent/ES2606137T3/es active Active
- 2011-07-08 JP JP2013517401A patent/JP5922115B2/ja active Active
- 2011-07-08 AR ARP110102454A patent/AR082135A1/es unknown
- 2011-07-08 US US13/808,903 patent/US10179791B2/en active Active
- 2011-07-08 BR BR112013000629-3A patent/BR112013000629B1/pt active IP Right Grant
- 2011-07-08 RU RU2013105490/04A patent/RU2602800C2/ru active
- 2011-07-08 CA CA2804143A patent/CA2804143C/en active Active
- 2011-07-08 WO PCT/EP2011/061599 patent/WO2012004378A1/en active Application Filing
- 2011-07-08 DK DK11730314.9T patent/DK2590955T3/en active
- 2011-07-08 MX MX2013000362A patent/MX347423B/es active IP Right Grant
- 2011-07-08 PT PT117303149T patent/PT2590955T/pt unknown
- 2011-07-08 PL PL11730314T patent/PL2590955T3/pl unknown
- 2011-07-08 EP EP16191215.9A patent/EP3144312A1/en not_active Withdrawn
- 2011-07-08 RU RU2016140266A patent/RU2016140266A/ru unknown
- 2011-07-08 KR KR1020137003334A patent/KR101889695B1/ko active IP Right Grant
- 2011-07-08 SG SG2013000625A patent/SG186926A1/en unknown
- 2011-07-08 NZ NZ605486A patent/NZ605486A/en unknown
- 2011-07-08 UY UY0001033497A patent/UY33497A/es not_active Application Discontinuation
-
2012
- 2012-12-31 IL IL224049A patent/IL224049B/en active IP Right Grant
-
2013
- 2013-01-07 ZA ZA2013/00153A patent/ZA201300153B/en unknown
- 2013-10-16 HK HK13111651.2A patent/HK1184153A1/zh unknown
-
2016
- 2016-08-05 US US15/230,063 patent/US9951084B2/en active Active
-
2018
- 2018-11-13 US US16/189,062 patent/US10807991B2/en active Active
-
2020
- 2020-08-31 US US17/007,359 patent/US11427598B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013000629A2 (pt) | derivados de amina espiro-cíclicos como moduladores s1p | |
PE20151651A1 (es) | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina | |
BR112013000627A2 (pt) | derivados heterocíclicos fundidos como moduladores s1p | |
JP2016515560A5 (pt) | ||
JP2019509276A5 (pt) | ||
EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
BR112015015812A2 (pt) | derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor | |
EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
JP2015537020A5 (pt) | ||
JP2014521688A5 (pt) | ||
IN2014DN03063A (pt) | ||
MX2012002534A (es) | Derivados de (tio) morfolina como moduladores de esfingosin-1-fosfato. | |
MX2015017343A (es) | Derivados de pirrolopiridina o pirazolopiridina. | |
EA201201677A1 (ru) | Производные гетероарилимидазолона в качестве ингибиторов jak | |
AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
EA201001181A1 (ru) | ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
BR112013001341A2 (pt) | compostos de pirimidina como inibidores de proteínas quinases ikk épsilon e/ou tbk-1, processo para a preparação dos mesmos e suas composições farmacêuticas | |
BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
RU2014120421A (ru) | Производные гетероарилгидроксамовой кислоты и их применение при лечении, облегчении течения или профилактике вирусных заболеваний | |
JP2015500842A5 (pt) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2011, OBSERVADAS AS CONDICOES LEGAIS. |